News

December 3, 2019
Caraway Therapeutics Expands Leadership Team With Appointment of Martin D. Williams as Chief Executive Officer and Cristina Csimma, PharmD, MHP, as Chair of the Board of Directors
Caraway Therapeutics, an emerging biopharmaceutical company pursuing novel approaches for the treatment of debilitating neurodegenerative diseases by preserving neurons, today announced it has appointed Martin D. Williams as Chief Executive Officer. » Full Story
October 10, 2019
Rheostat Therapeutics Announces Rebrand to Caraway Therapeutics and New Kendall Square Office
Rheostat Therapeutics, an emerging biopharmaceutical company pursuing novel approaches for the treatment of debilitating neurodegenerative diseases by preserving neurons, today announced the company has changed its name to Caraway Therapeutics. » Full Story
November 26, 2018
Rheostat Therapeutics Announces $23 Million Series A Financing To Develop Potential Treatments for Neurodegenerative Diseases
Rheostat Therapeutics, a biotech company focused on the discovery of novel treatments for neurodegeneration, cognition and rare diseases, today announced the close of a Series A financing round totaling $23 million. » Full Story